Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYNMOBI vs DOSTINEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Treatment of hypomobility, off episodes, and end-of-dose wearing-off in patients with advanced Parkinson disease,Off-label: Treatment of erectile dysfunction
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (prolactinomas),Off-label: Reduction of breast engorgement postpartum (non-FDA)
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Extensively metabolized in the liver by glucuronidation via UGT1A1 and UGT2B7; also undergoes sulfation. N-demethylation via CYP1A2 and CYP3A4 may occur. No active metabolites identified.
Extensively metabolized in the liver, primarily via hydrolysis of the acylurea bond; CYP3A4 is involved in minor hydroxylation pathways.
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Apomorphine is approximately 90% bound to plasma proteins, primarily albumin.
Approximately 41–42% bound to plasma proteins, primarily albumin.
The volume of distribution is approximately 200 L (about 2.9 L/kg for a 70 kg individual), indicating extensive tissue distribution.
The apparent volume of distribution is approximately 150–200 L, indicating extensive tissue distribution. In L/kg (assuming 70 kg), Vd ≈ 2.1–2.9 L/kg. This large Vd suggests sequestration in tissues, including the pituitary.
Bioavailability of apomorphine is low and variable after oral administration (<5%). Subcutaneous administration provides 100% bioavailability. Sublingual film (KYNMOBI) has a bioavailability of approximately 18% relative to subcutaneous injection.
Oral bioavailability is approximately 50–60% due to first-pass metabolism. Food does not significantly affect absorption.
No specific dose adjustment provided; use caution in severe renal impairment (Cr Cl <30 m L/min) as data limited.
No specific recommendations; use caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No specific dose adjustment provided; use caution in Child-Pugh Class C as data limited.
No specific recommendations; use caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
Safety and effectiveness in pediatric patients have not been established.
Safety and effectiveness in pediatric patients have not been established; not recommended.
No specific geriatric dose adjustment; pharmacokinetics similar to younger adults; monitor for hypotension and hallucinations.
No specific dose adjustment; monitor for orthostatic hypotension and neuropsychiatric effects.
KYNMOBI can cause serious adverse reactions, including severe nausea and vomiting, symptomatic orthostatic hypotension (particularly with concomitant antihypertensives), syncope, QT prolongation, and hallucinations/psychosis. It should not be used with serotonergic drugs due to risk of serotonin syndrome.
None.
Orthostatic hypotension/syncope; nausea/vomiting (pretreat with antiemetic); hallucinations/psychosis; impulse control disorders; dyskinesias; coronary and cerebral ischemia; QT prolongation; priapism; somnolence/sudden sleep onset; falls; cardiac valvulopathy (due to ergot-like activity); potential for abuse (dopaminergic dysregulation syndrome).
Risk of valvulopathy and cardiac fibrosis with long-term use, especially at high cumulative doses,May cause hypotension, syncope, or orthostatic hypotension,Monitor for pleural effusion, pulmonary fibrosis, and pericarditis,Impulse control disorders (e.g., pathological gambling, hypersexuality),Somnolence and sudden sleep onset; caution when driving
Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, triptans) due to risk of serotonin syndrome; severe hepatic impairment; history of QT prolongation or concomitant QT-prolonging drugs; hypersensitivity to apomorphine or its components; use of 5-HT3 antagonists (e.g., ondansetron) for antiemesis (risk of profound hypotension).
Uncontrolled hypertension,Preeclampsia or eclampsia,Known hypersensitivity to ergot derivatives,History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
No specific food interactions are reported; however, administer on an empty stomach or at least 30 minutes before or after meals to optimize absorption. Avoid grapefruit juice as it may increase apomorphine levels. Alcohol should be avoided due to additive sedative and hypotensive effects.
No specific food restrictions. However, high-fat meals may increase absorption, but no dose adjustment is required. Avoid alcohol due to increased risk of dizziness and gastrointestinal upset. Grapefruit juice may inhibit CYP3A4 and increase cabergoline levels; consider avoiding large quantities.
Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times the maximum human dose, respectively, on a mg/m² basis). No fetal malformations were observed. However, embryolethality and decreased fetal body weight occurred at maternally toxic doses in rabbits. Use during pregnancy only if potential benefit justifies potential risk to the fetus; first trimester risks are unknown.
Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing reports of spontaneous abortion and congenital anomalies (limb defects, cardiac) but causal relationship unestablished. Avoid in pregnancy unless benefit outweighs risk. Use only after excluding pregnancy and using effective contraception during treatment until 1 month after discontinuation.
It is not known whether apomorphine is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk. Peak milk concentration ~0.15-0.25 ng/m L after 0.25 mg oral dose. M/P ratio unknown. Due to potential for suppression of lactation and unknown infant effects, contraindicated in breastfeeding women. Discontinue nursing or avoid drug.
Pharmacokinetic changes during pregnancy may alter apomorphine clearance, although specific data are lacking. No dosing adjustment studies have been conducted. Use caution and monitor clinical response; dose adjustment may be necessary based on efficacy and tolerability, but no standard recommendation exists.
No specific dose adjustments recommended due to contraindication in pregnancy. If inadvertently exposed, discontinue immediately. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but no formal dose adjustment studies exist. Use is not advised.
KYNMOBI (apomorphine sublingual film) is a rapid-onset, non-ergoline dopamine agonist for acute, intermittent treatment of OFF episodes in Parkinson disease. Onset of action occurs within 15-30 minutes. Administer film under the tongue and allow to dissolve completely; do not swallow saliva until dissolved. Nausea and vomiting are common pre-treatment with an antiemetic (e.g., trimethobenzamide) for at least 2 days prior. Monitor for hypotension, syncope, and QT prolongation. Avoid use with 5-HT3 antagonists (e.g., ondansetron) due to risk of profound hypotension. Do not use with apomorphine injection as it may lead to cumulative adverse effects.
Dostinex (cabergoline) is a long-acting dopamine D2 receptor agonist used primarily for hyperprolactinemia. Its half-life of 63-69 hours allows once or twice weekly dosing. Monitor for valvular heart disease with echocardiography before and during therapy due to risk of fibrotic reactions, especially at high doses used in Parkinson's disease. Avoid concurrent use with CYP3A4 inhibitors (e.g., macrolides, azole antifungals) that can increase cabergoline levels. Titrate dose gradually to minimize orthostatic hypotension and gastrointestinal side effects.
Place the film under your tongue and let it dissolve completely. Do not chew, swallow, or move the film with your tongue.,Do not eat or drink until the film has fully dissolved to ensure proper absorption.,Take KYNMOBI only at the first sign of an OFF episode to improve mobility.,You may experience nausea and vomiting; your doctor may prescribe an antiemetic to take before your first dose.,Avoid alcohol, as it may increase sedation and hypotension.,Do not drive or operate machinery until you know how KYNMOBI affects you, as it may cause dizziness, drowsiness, or sudden sleep onset.,Report any unusual urges (gambling, sexual, spending) to your doctor as these can occur with dopamine agonists.,Do not use this medicine more than 5 times per day or more often than every 2 hours.
Take exactly as prescribed, typically once or twice per week; do not double doses if missed. Take with food if nausea occurs. Avoid alcohol as it may increase side effects. Report any shortness of breath, cough, chest pain, or swelling of extremities immediately (signs of valvulopathy). Do not drive or operate machinery until you know how the medication affects you, as it may cause dizziness or drowsiness. Women who may become pregnant should use effective contraception; stop cabergoline if pregnancy is confirmed. Inform all healthcare providers about this medication, including before any surgery or dental procedures. Keep out of reach of children and store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYNMOBI vs DOSTINEX, answered by our medical review team.
KYNMOBI is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.. DOSTINEX is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYNMOBI and DOSTINEX depend on the specific clinical indication. These are both Dopamine Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYNMOBI is: Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.. The standard adult dose of DOSTINEX is: 0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYNMOBI and DOSTINEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYNMOBI is classified as Category C. Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times . DOSTINEX is classified as Category C. Category B: Animal studies (rats, rabbits) at doses up to 2.5 mg/kg/day showed no teratogenic effects but embryotoxicity at high doses. No adequate human studies. Post-marketing re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.